Obeticholic acid, an FXR agonist, is approved as a second-line therapy for primary biliary cholangitis 255, and both it and other FXR agonists, such as vonafexor are being investigated as treatments for MASLD fibrosis 256. Here, NR1H4 is linked to biliary liver cirrhosis.